The biggest funding round in September was into London-based ‘developer-first’ cyber security platform Snyk, which raised £156m in a Series D round.
Hull-based Connexin raised an initial commitment of up to £80m as it aims to make UK cities smarter and safer.
Cambridge-headquartered clinical stage BioTech firm Immune Regulation closed a Series B round of £40.6m.
Also raising around £30m in September were CentralNic Group and data intelligence firm Ripjar.
Visiting our funding page every weekday morning for an up-to-date view on the latest tech investments.
- Snyk (London) – £156m
- Connexin (Yorkshire and Humberside) – £80m
- Immune Regulation (East of England) – £40.6m
- CentralNic Group (London) – £30m
- Ripjar (South West) – £28m
- ClearBank/Tide (London) – £25m
- BIMA (London) – £23m
- MiNA Therapeutics (London) – £23m
- Uncapped (London) – £20.5m
- AppyWay (London) – £20m
- TrueLayer (London) – £19.7m
- RightSpend (London) – £17m
- Celsius Network (London) – £15.2m
- Huboo (South West) – £14m
- PragmatIC (East of England) – £13m
- Kbox Global (London) – £12m
- CloudMargin (London) – £11.8m
- InfoSum (South East) – £11.4m
- Chip (London) – £10.7m
- Medefer (London) – £10m
- Acin (London) – £9.3m
- Moteefe (London) – £8.3m
- Signifier Medical Technologies (London) – £7.7m
- Funding Xchange (London) – £7.7m
- Dendra Systems (South East) – £7.7m